The history of antibiotics has repeated itself: drugs are discovered, but bacterial evolution can soon render them ineffective in treating infections. Resistance is fueled by injudicious use of existing drugs and compounded by a failure to develop novel new ones. Many major pharmaceutical companies have limited their investments in this antibiotic innovation, and only two new classes of these substances have reached the market in the past 30 years.
Pew’s work on antibiotics and innovation develops and supports policies that will spur innovation of new antibiotics to fight infections today and to ensure a healthy nation in the future.
Our WorkView All
Pew Testimony on Antibiotic Resistance Before the Presidents Council of Advisors on Science and Technology
The President’s Council of Advisors on Science and Technology held a public meeting on April 4 to discuss the issue of antibiotic resistance. Senior director of drugs and medical devices Allan Coukell testified on the need to spur the development of new antibacterial drugs and to better collect data on antibiotic use both in both agriculture and humans. Read More
On Tuesday, June 10, Pew submitted comments to the U.S. House of Representatives Energy and Commerce Committee’s "21st Century Cures" initiative, a Congressional effort to address issues in drug and device discovery and development. Pew's comments addressed challenges in antibiotic development and the expansion of health information technology’s potential impact on medical device... Read More